Dowsett M et al. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. SABCS 2023;Abstract 4.

Trapani D et al. Identifying patterns and barriers in OncotypeDX recurrence score testing in older patients with early-stage, estrogen receptor-positive breast cancer: Implications for guidance and reimbursement. JCO Oncol Pract 2023;19(8):560-70. Abstract

Matthew P Goetz, MD

Brown LC et al. Evolution of PAM50 intrinsic subtypes and ROR scores in HR+ HER2- breast cancers diagnosed in premenopausal women: A secondary analysis of the SOFT trial. ASCO 2023;Abstract 504.

Kalinsky KM et al. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (ln), hormone receptor-positive (HR+) and HER2-negative breast cancer (bc) with recurrence score (RS) of ≤25 randomized to endocrine therapy (et) +/- chemotherapy (ct): SWOG S1007 (RxPONDER). SABCS 2021;Abstract GS2-07.

Luen SJ et al. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023;34(4):397-409. Abstract

Harold J Burstein, MD, PhD

Blotta DA et al. Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients. ASCO 2023;Abstract 527.

Curigliano G et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol 2023;34(11):970-86. Abstract

Gray R et al. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,999 pre-menopausal women in 25 randomized trials. ASCO 2023;Abstract 503.

Pagani O et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 2023;41(7):1376-82. Abstract

Partridge AH et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med 2023;388(18):1645-56. Abstract

Sara A Hurvitz, MD, FACP

Cardoso F et al. KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. ESMO 2023;Abstract LBA21.

Harbeck N et al. Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer. ESMO 2023;Abstract 63P.

Loi S et al. A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). ESMO 2023;Abstract LBA20.

Salmon DJ et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the Phase III NATALEE trial. ASCO 2023;Abstract LBA500.

Joyce O’Shaughnessy, MD

Geyer CE Jr et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 2022;33(12):1250-68. Abstract

Schmid P et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. ESMO 2023;Abstract LBA18.

Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-67. Abstract

Sharma P et al. Assessment of phase 3 randomized clinical trials including patients with leptomeningeal disease. JAMA Oncol 2023;9(4):566-7. Abstract

Sharma P et al. Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). ASCO 2022;Abstract 513.

Tolaney SM et al. ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery. ASCO 2023;Abstract TPS619.

Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO 2022;Abstract VP1-2022.

Lajos Pusztai, MD, DPhil, FASCO

Cailleux F et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis Onc 2022:e2200148. Abstract

Pusztai L et al. Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy. SABCS 2023;Abstract PS 06-02.

Shaw J et al. Serial postoperative ctDNA monitoring of breast cancer recurrence. ASCO 2022;Abstract 562.

Yu L et al. Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels. Plos One 2022;17(4):e0266889. Abstract